Business Context and Reporting Period
This Form 8-K filing by AcelRx Pharmaceuticals, Inc. (ACRX) reports on events occurring on May 30, 2019. The company, a Delaware corporation, entered into a new material definitive agreement to secure financing and simultaneously terminated a prior loan agreement.
Key Financial Metrics and Transaction Details
- New Debt Facility: Entered into a Loan and Security Agreement with Oxford Finance LLC for a term loan of $25.0 million, funded on May 30, 2019.
- Use of Proceeds: Approximately $9.0 million was used to repay outstanding obligations under a prior agreement with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc.
- Interest Rate: Floating rate equal to the greater of 30-day U.S. LIBOR or 2.50%, plus 6.75%.
- Repayment Terms: Interest-only payments for the first 12 months, followed by principal and interest amortization over 36 months. Final maturity date is June 1, 2023.
- Extension Option: The interest-only period may be extended to 24 months if the company raises at least $45.0 million in unrestricted net cash proceeds from equity or partnership deals by June 30, 2020.
- Fees: A 5% "Final Fee" is due upon maturity or prepayment. Prepayment fees range from 1% to 2% depending on the timing of repayment.
- Liquidity Covenant: The company must maintain unrestricted cash of at least $5.0 million in controlled accounts.
- Equity Issuance: Issued warrants to the lender for 176,679 shares of common stock with an exercise price of $2.83 per share.
Material Changes Versus Prior Period
The company terminated its prior loan agreement with Hercules Technology entities effective May 30, 2019, after repaying all amounts owed. No termination penalty was incurred. This transaction replaced the prior debt structure with the new $25.0 million facility from Oxford Finance LLC, which includes a security interest in all company assets except intellectual property (subject to a negative pledge).
Guidance, Risks, and Covenants
- Covenants: The agreement restricts the company's ability to declare dividends, repurchase equity, incur additional indebtedness or liens, make investments, engage in mergers/acquisitions, or change business locations without consent.
- Events of Default: Include failure to make payments, insolvency, material adverse changes, delisting of stock, or unsatisfied judgments exceeding $500,000.
- Default Consequences: A default interest rate of an additional 5% may be applied, and the lender may declare all obligations immediately due and payable.
- Unusual Items: The filing notes the issuance of warrants was made under Section 4(a)(2) of the Securities Act of 1933 as a private placement to accredited investors.
Investor Verification Checklist
- Verify the current cash balance to ensure compliance with the $5.0 million unrestricted cash covenant.
- Monitor the company's progress toward raising $45.0 million in equity or partnership proceeds by June 30, 2020, to qualify for the interest-only period extension.
- Review the impact of the 5% final fee and potential prepayment fees on future liquidity and refinancing costs.
- Assess the dilution impact of the 176,679 warrants issued to the lender.
- Confirm the status of the company's intellectual property, which is excluded from the security interest but subject to a negative pledge.